Ford F- Ford revenue increased 17% from last year to $33.1 billion and reduced its debt by $2.5 billion. The result showed an increase of $466 million over the first quarter of 2010, and is the best first quarter earnings since 1998. Competitors- General Motors Company (GM), Toyota Motor Corp (TM), Daimler AG (DDAIF)
General Motors Company GM- So far this year, GM shares have fallen 13.5% to $32. In the past year, the shares have traded as low as $29.17 and as high as $39.48. On average, 16158100 shares of GM exchange hands on a given day and today's volume is recorded at 3118842. Competitors- HONDA MOTOR CO (HMC), Nissan Motor Co (NSANY), Tesla Motors Inc (TSLA)
Gen-Probe Incorporated GPRO- Gen-Probe Inc., the tester of sexually transmitted diseases that jumped 18 percent on speculation it will be sold, may still be worth $1.3 billion more in a takeover by Novartis AG (NOVN) or Life Technologies Corp. (LIFE). Gen-Probe is twice as profitable per dollar of reinvested earnings as rival Qiagen NV (QGEN), while its gross margin outstrips Cepheid Inc. (CPHD) by 36 percent. Competitors- Cepheid (CPHD), GenMark Diagnostics (GNMK), IRIS International (IRIS)
NetSuite Inc. N- NetSuite Inc. provides an on-demand, integrated business management application suite, which provides Accounting/Enterprise Resource Planning (ERP), Customer Relationship Management (CRM) and Ecommerce functionality to medium-sized businesses and divisions of large companies. It also offer customers support and professional services related to the suite. The Company delivers the suite over the Internet as a subscription using the SaaS model. Competitors- Epicor Software Corp (EPIC), Oracle Corporation (ORCL), SAP AG (SAP)
Nortel Networks Corporation (USA) NRTLQ- Nortel Networks Corp.'s European units are pressing more than $10 billion worth of claims against their Canadian parent, including a claim for $4.6 billion worth of damages for alleged mismanagement under French law, court documents say. If the Nortel European claims survive court tests, unsecured creditors of the Canadian parent will see a significant reduction in the amounts they will receive, Ernst & Young said. Competitors- Sierra Wireless (SWIR), Ciena Corporation (CIEN), TransAKT Ltd (TAKD)
YRC Worldwide Inc. YRCW- RCW closed Friday at $1.98/share. Reducing that to 2.5% means a single share after dilution will have a market value of $0.0495. The stock isn't even worth a nickel. It will be worth even less if management exercises further dilutive rights after the new equity is issued. The earnings call on May 6 will reveal just how long the proposed new financing will carry the company. The company's total cash flow in 2010 was about $61.5mm, so $100mm in new financing would theoretically last more than a year at their present burn rate. Competitors- Arkansas Best Corporation (ABFS), Con-way Inc (CNW), Saia Inc (SAIA)
International Paper Company IP- International Paper Co is expected to earn $0.59 per share for quarter ended Mar 11. Estimates from Wall Street analysts ranged from as low as $0.50 per share to as high as $0.63 per share. For the same quarter last year, the company earned $0.04 per share. Revenues are expected to come in at $6.36B. Shares of International Paper Co IP traded higher by 1.75% or $0.525/share to $30.505. Competitors- Clearwater Paper Corp (CLW), P.H. Glatfelter Company (GLT), Wausau Paper Corp (WPP)
Apple Inc. AAPL- Apple Inc. announced that for the third quarter of 2011, it expect revenue of about $23 billion and diluted earnings per share (EPS) of about $5.03. According to Reuters Estimates, analysts are expecting the Company to report revenues of $23.8 billion and EPS of $5.24 for the third quarter of 2011. Competitors- Hewlett-Packard Company (HPQ), Dell Inc (DELL), Microsoft Corporation (MSFT)
Oncothyreon Inc. ONTY- Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. Oncothyreon's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's lead product candidate under clinical development is a vaccine it calls Stimuvax. Stimuvax incorporates a 25 amino acid sequence of the cancer antigen MUC1, in a liposomal formulation. Competitors- Agenus Inc (AGEN), SuperGen Inc. (SUPG), Celgene Corporation (CELG)
Spectrum Pharmaceuticals, Inc. SPPI- Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company has a fully developed commercial infrastructure that markets and sells two drugs in the United States, Zevalin and Fusilev. The Company has several drug candidates in development, which include apaziquone (EOquin), which is being studied in two large Phase III clinical trials for non-muscle invasive bladder cancer (NMIBC) under a strategic collaboration with Allergan; and belinostat, a drug partnered with TopoTarget A/S to jointly develop. Competitors- Par Pharmaceutical (PRX), Bristol Myers Squibb Co (BMY), Johnson & Johnson (JNJ)
Berkshire Hathaway Inc. BRK- The American investment guru, Warren Buffett, has admitted to shareholders he made a big mistake over a senior executive who unexpectedly resigned from his company Berkshire Hathaway. Mr Buffett said he should have been quicker to question the executive, David Sokol, about the shares he bought in an oil company before it was taken over by Berkshire Hathaway. Berkshire Hathaway (BRKA) accused former exec David Sokol of deceiving the company by failing to disclose his interest in takeover target Lubrizol (LZ) . Sokol, who made a $3 mil profit on his shares in Lubrizol, has denied wrongdoing. Competitors- W.R. Berkley Corporation (WRB), American Intl. Group (AIG), Wesco Financial Corp (WSC)
Berkshire Hathaway Inc. BRK- One can think of Berkshire Hathaway as one of the largest mutual funds on earth which has an outperforming record. The company mostly invests in financial stocks which are deemed safe by Berkshire. Interestingly, since Stifel Nicolaus upgraded Berkshire's stocks in February 28, the stock is down by 6%. Buffett's performance usually surpasses analyst estimates. Competitors- RLI Corp (RLI), CNA Financial Corporation (CNA), Global Indemnity plc (GBLI)
BJ's Wholesale Club Inc. BJ- BJ's Wholesale Club, Inc. announced that for fiscal 2011, it is expecting between 5.5% and 7.5% increase in net sales and EPS between $2.62 and $2.82. The Company reported revenues of $10.877 billion in fiscal 2010. According to Reuters Estimates, analysts on an average are expecting the Company to report revenues of $11.712 billion and EPS of $2.82 for fiscal 2011. Competitors- PriceSmart Inc. (PSMT), Costco Wholesale Corp. (COST), Wal-Mart Stores (WMT)
Citigroup Inc. C- Citigroup Inc. has said that emerging-market equity funds have recorded a fifth week of inflows. Citigroup Inc. C shares were at 4.59 at the end of the last day's trading. There's been a -6.4% change in the stock price over the past 3 months. Competitors- Bank of America Corp (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC)
Kindred Healthcare, Inc. (NYSE:KND)- Kindred Healthcare, Inc. (Kindred) is a healthcare services company that through its subsidiaries operates hospitals, nursing and rehabilitation centers and a contract rehabilitation services business across the United States. As of December 31, 2009, its hospital division operated 83 long-term acute care (LTAC) hospitals in 24 states. The Company's health services division operated 222 nursing and rehabilitation centers in 27 states. Competitors- RehabCare Group (RHB), National HealthCare Corp (NHC), HEALTHSOUTH Corp (HLS)
SUBSCRIBE to CEOWORLD Magazine Digital & SAVE UP TO 80% OFF. Reaching more than 85,000 Chief Executive Officers and decision making executives who serve on the boards of leading companies. SUBSCRIBE NOW!!!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
